Study finds Pfizer’s antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week
Pfizer’s COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although…
Read More
‘Remote work is here to stay,’ says New York Federal Reserve
Employees in the New York area who work from home are reluctant to give up…
Read More